NO995812L - Metode og sammensetninger for administrering av taxaner oralt til pasienter - Google Patents

Metode og sammensetninger for administrering av taxaner oralt til pasienter

Info

Publication number
NO995812L
NO995812L NO995812A NO995812A NO995812L NO 995812 L NO995812 L NO 995812L NO 995812 A NO995812 A NO 995812A NO 995812 A NO995812 A NO 995812A NO 995812 L NO995812 L NO 995812L
Authority
NO
Norway
Prior art keywords
patients
administration
compositions
taxanes orally
taxanes
Prior art date
Application number
NO995812A
Other languages
English (en)
Norwegian (no)
Other versions
NO995812D0 (no
Inventor
Samuel Broder
Kenneth L Duchin
Sami Selim
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of NO995812D0 publication Critical patent/NO995812D0/no
Publication of NO995812L publication Critical patent/NO995812L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO995812A 1997-05-27 1999-11-26 Metode og sammensetninger for administrering av taxaner oralt til pasienter NO995812L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86351397A 1997-05-27 1997-05-27
PCT/US1998/007776 WO1998053811A1 (en) 1997-05-27 1998-04-22 Method and compositions for administering taxanes orally to human patients

Publications (2)

Publication Number Publication Date
NO995812D0 NO995812D0 (no) 1999-11-26
NO995812L true NO995812L (no) 2000-01-25

Family

ID=25341241

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995812A NO995812L (no) 1997-05-27 1999-11-26 Metode og sammensetninger for administrering av taxaner oralt til pasienter

Country Status (23)

Country Link
EP (1) EP0994706B1 (xx)
JP (1) JP2002500667A (xx)
KR (1) KR100615783B1 (xx)
CN (2) CN1261275A (xx)
AR (1) AR012731A1 (xx)
AT (1) ATE308365T1 (xx)
AU (1) AU7130098A (xx)
BR (1) BR9809694A (xx)
CA (1) CA2290446C (xx)
CZ (1) CZ9904244A3 (xx)
DE (1) DE69832173T2 (xx)
DK (1) DK0994706T3 (xx)
ES (1) ES2247690T3 (xx)
HK (1) HK1026637A1 (xx)
HU (1) HUP0003546A3 (xx)
IL (2) IL132992A0 (xx)
NO (1) NO995812L (xx)
PL (1) PL337064A1 (xx)
RU (1) RU2205005C2 (xx)
SK (1) SK157599A3 (xx)
UA (1) UA74767C2 (xx)
WO (1) WO1998053811A1 (xx)
ZA (1) ZA984268B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
AU3574097A (en) * 1997-06-20 1999-01-04 Baker Norton Pharmaceuticals, Inc. Soluble prodrugs of paclitaxel
GB9718903D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
EP1749540B1 (en) 1999-05-17 2010-10-13 Cancer Research Ventures Limited Compositions for improving bioavailability of orally administered drugs
HUP0203303A3 (en) * 1999-10-27 2005-01-28 Baker Norton Pharma Compositions for administering taxanes orally to human patients
KR20020013174A (ko) * 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
EP1365759A2 (en) * 2001-01-18 2003-12-03 PHARMACIA & UPJOHN COMPANY Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1623706A3 (en) * 2001-02-28 2006-02-22 Bristol-Myers Squibb Company Metronomic dosing of taxanes for inhibiting tumor growth
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
US7063977B2 (en) 2001-08-21 2006-06-20 Bristol-Myers Squibb Company Enzymatic resolution of t-butyl taxane derivatives
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
NZ596868A (en) * 2009-06-02 2014-04-30 Nikan Pharmaceuticals Llc Antagonism of human formyl peptide receptor for treatment of disease
EP4059497A1 (en) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP4308114A1 (en) * 2021-03-17 2024-01-24 Dompe' Farmaceutici SpA C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
CA2098198A1 (en) * 1990-12-18 1992-06-18 Ann Christie King Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
CZ283038B6 (cs) * 1991-01-11 1997-12-17 Laboratoires Glaxo Sa Akridinové deriváty, způsob výroby a farmaceutické prostředky s jejich obsahem
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
ES2126919T3 (es) * 1994-07-26 1999-04-01 Indena Spa Taxanos semisinteticos con actividad antitumoral.
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
JPH11507356A (ja) * 1995-06-07 1999-06-29 アブマックス，インコーポレイティド 経口薬理化合物の生物有用性を高めるためのエッセンシャルオイルの利用
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2221444A1 (en) * 1996-01-31 1997-08-07 Steven B. Hansel A method of making pharmaceutically active taxanes orally bioavailable
US6025359A (en) * 1996-06-17 2000-02-15 Eli Lilly And Company Drug resistance and multidrug resistance modulators
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU756752B2 (en) * 1998-04-01 2003-01-23 Skyepharma Canada Inc. Anticancer compositions

Also Published As

Publication number Publication date
CN1550231A (zh) 2004-12-01
KR100615783B1 (ko) 2006-08-25
NO995812D0 (no) 1999-11-26
IL132992A (en) 2006-08-20
WO1998053811A1 (en) 1998-12-03
ATE308365T1 (de) 2005-11-15
RU2205005C2 (ru) 2003-05-27
ES2247690T3 (es) 2006-03-01
BR9809694A (pt) 2000-10-03
DE69832173T2 (de) 2006-08-03
ZA984268B (en) 1999-06-23
UA74767C2 (en) 2006-02-15
EP0994706A4 (en) 2001-05-16
CZ9904244A3 (cs) 2001-10-17
JP2002500667A (ja) 2002-01-08
IL132992A0 (en) 2001-03-19
EP0994706A1 (en) 2000-04-26
AR012731A1 (es) 2000-11-08
KR20010013025A (ko) 2001-02-26
PL337064A1 (en) 2000-07-31
HUP0003546A3 (en) 2002-12-28
AU7130098A (en) 1998-12-30
CA2290446C (en) 2008-01-29
HUP0003546A2 (hu) 2002-11-28
SK157599A3 (en) 2002-10-08
EP0994706B1 (en) 2005-11-02
CA2290446A1 (en) 1998-12-03
DK0994706T3 (da) 2006-03-06
HK1026637A1 (en) 2000-12-22
CN1261275A (zh) 2000-07-26
DE69832173D1 (de) 2005-12-08

Similar Documents

Publication Publication Date Title
DK1079809T3 (da) Enterisk overtrukket farmaceutisk sammensætning og fremgangsmåde til fremstilling deraf
NO994778D0 (no) FremgangsmÕter og sammensetninger for behandling av tarmbetennelse
NO995812D0 (no) Metode og sammensetninger for administrering av taxaner oralt til pasienter
IS2058B (is) Ný taxóíð, aðferð til framleiðslu þeirra og lyfjasamsetningar sem innihalda þau
NO20004741L (no) Farmasöytiske blandinger for forlenget peptidfrigjöring og fremstillingsmetode
NO20010260L (no) Tarmbeskyttelsesbelagt farmasøytisk tablett og fremgangsmÕte for fremstilling
IS5097A (is) Fenófíbrat lyfjasamsetning með háa lífeðlisfræðilega upptöku og aðferð til framleiðslu hennar
NO994757L (no) Fremgangsmåte for oral administrasjon av proteiner
DK0890359T3 (da) Beta-Lactam-antibiotikumholdige tabletter og fremgangsmåde til fremstilling deraf
IS5245A (is) Lyfjablanda úr ómeprasól
NO975759D0 (no) Inokuleringsmiddel og fremgangsmåte for fremstilling av inokuleringsmiddel
IS5747A (is) Oxazólidínón afleiður, aðferð fyrir framleiðslu þeirra og lyfjasamsetninga sem innihalda þær
NO973479L (no) Substituerte heterosykliske forbindelser, fremgangsmåte for fremstilling og farmasöytiske blandinger inneholdende samme
NO20002851D0 (no) Blandinger for nasal administrasjon av medikamenter
NO984878D0 (no) Fremstilling og anvendelse som medikamenter av 3-alkoksypyridin-2-karboksylsyreamidestere
PT1039909E (pt) Metodo de producao e composicao de uma preparacao oral de itraconazole
IS4635A (is) 4-fenýlamínóþíasólafleiður, aðferð við að framleiða þær og lyfjablöndur sem innihalda þær
IS4805A (is) Aðferð til meðhöndlunar og lyfjasamsetning
PL341230A1 (en) Solid dosage forms of ribavirin for oral administration and method of obtaining them
DK1334717T3 (da) Farmaceutiske sammensætninger til oral og topisk administrering
EP1181022A4 (en) MEDICAL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
NO20022008D0 (no) Fremgangsmåte og preparater for oral administrering av taxaner til humane pasienter
NO924528L (no) Derivater av humant gallesalt-stimulert lipase og farmasoeytiske sammensetninger som inneholder disse
IS2199B (is) Svæfandi ß-karbólín afleiður, aðferð til framleiðslu þeirra og notkun þeirra sem læknislyf
NO20021832D0 (no) Farmasöytiske sammensetninger av tizoksanid og nitazoksanid

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application